ERBB2 and breast cancer: Previously, phase II clinical trial investigating the efficacy of GP2 peptide vaccination in combination with immunoadjuvant GM-CSF treatment showed CD8+ T cells activation with improved 5-year DFS in HER2+ BC patients (155).